iORGANBIO and Mitsui Chemicals Partner to Advance AI-Driven Cell and Organoid Production

MORRISVILLE, N.C., Nov. 10, 2026 /CourierPR/ -- iORGANBIO Inc., a biotechnology company based in Morrisville, North Carolina, has secured investment from Mitsui Chemicals Inc., a leading Japanese chemical manufacturer. The investment was made through Mitsui Chemicals’ corporate venture capital fund, 321Catalyst™. This collaboration aims to advance the development of human cells and organoids, which are crucial for drug discovery and regenerative medicine.

iORGANBIO has developed a proprietary platform that integrates artificial intelligence (AI), single-cell analysis, and robotics into a closed-loop autonomous laboratory. This platform enables the efficient and consistent production of human cells and organoids, which are essential for evaluating drug candidates and advancing cell therapy research.

Founded in July 2024, iORGANBIO is led by CEO Daniel Delubac and operates from its headquarters in Morrisville, North Carolina. The company's Physical AI platform integrates AI, single-cell analysis, and robotics to produce target human cells and organoids with high uniformity and reproducibility. iORGANBIO supports pharmaceutical and biotechnology companies by designing cell models that replicate the identity and function of cells inside the human body for evaluating drug candidates and by manufacturing cells for cell therapy research and development.

Mitsui Chemicals, with its President & CEO, Satoshi Ichimura, leading the company, sees this partnership as a significant step in contributing to greater efficiency in drug discovery and advancements in cell therapy and regenerative medicine.

Going forward, the companies will explore jointly developing new drug discovery technologies that could complement or serve as alternatives to animal testing. These technologies include efficacy and safety assessments using cells and organoids, as well as related materials suitable for cell culture. The partnership is expected to enhance the quality and consistency of cells and organoids, enabling the production of cell types and organoids that have previously been difficult to manufacture.

Specifically, the collaboration will leverage Mitsui Chemicals' materials design and development capabilities, including its InnoCell™ cell culture plates. By combining their respective technologies and optimizing the culture conditions that allow cells to grow and function consistently, the two companies aim to improve the quality of cells and organoids and enable the production of cell types and organoids that have previously been difficult to manufacture.

This partnership underscores the growing importance of AI and advanced biotechnology in the pharmaceutical and biotechnology industries. By leveraging their respective strengths, iORGANBIO and Mitsui Chemicals aim to drive innovation and improve the efficiency of drug development processes. The collaboration is expected to have a significant impact on the future of drug discovery and regenerative medicine, potentially reducing the time and cost associated with developing new treatments.